Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A607576-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,334.90 | |
A607576-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,000.90 |
Synonyms | AM-1710|R0GPP0WDF9|3-(1,1-Dimethylheptyl)-1-hydroxy-9-methoxy-6H-dibenzo(b,d)pyran-6-one|UNII-R0GPP0WDF9|AM1710|335371-36-3|CHEMBL266712|6H-Dibenzo(b,d)pyran-6-one, 3-(1,1-dimethylheptyl)-1-hydroxy-9-methoxy-|1-hydroxy-9-methoxy-3-(2-methyloctan-2-yl)benz |
---|---|
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of CB 1 receptor;Agonist of CB 2 receptor |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1-hydroxy-9-methoxy-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one |
---|---|
INCHI | InChI=1S/C23H28O4/c1-5-6-7-8-11-23(2,3)15-12-19(24)21-18-14-16(26-4)9-10-17(18)22(25)27-20(21)13-15/h9-10,12-14,24H,5-8,11H2,1-4H3 |
InChi Key | ZAIKPEWFCSQNQB-UHFFFAOYSA-N |
Canonical SMILES | CCCCCCC(c1cc(O)c2c(c1)oc(=O)c1c2cc(OC)cc1)(C)C |
Isomeric SMILES | CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(=O)C3=C2C=C(C=C3)OC)O |
PubChem CID | 11268660 |
ChEMBL Ligand | CHEMBL266712 |
---|---|
PubChem CID | 11268660 |
BindingDB Ligand | 50228073 |
GPCRdb Ligand | AM1710 |
Enter Lot Number to search for COA:
1. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA, Sun SC, Resnick L, Chlenov M, He Y et al.. (2007) Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers.. Br J Pharmacol, 151 (7): (1061-70). [PMID:17549048] |
2. Khanolkar AD, Lu D, Ibrahim M, Duclos Jr RI, Thakur GA, Malan Jr TP, Porreca F, Veerappan V, Tian X, George C et al.. (2007) Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.. J Med Chem, 50 (26): (6493-500). [PMID:18038967] |
3. Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG. (2011) Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.. Pharmacol Biochem Behav, 98 (4): (493-502). [PMID:21382397] |
4. Dhopeshwarkar A, Murataeva N, Makriyannis A, Straiker A, Mackie K. (2017) Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.. J Pharmacol Exp Ther, 360 (2): (300-311). [PMID:27927913] |
5. Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG. (2019) Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.. Mol Pharmacol, 95 (2): (155-168). [PMID:30504240] |